 Aprea Therapeutics Inc NASDAQ:APRE shares are trading higher by 46 at 7.07 after the company announced the Phase 12 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met the complete remission CR primary efficacy endpoint. According to the press release, in 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37 and the composite response rate of CR plus CR with incomplete hematologic recovery CRi, CRCRi, was 53. 